Antifungal Susceptibility Testing: Practical Aspects and Current Challenges

DOI Web Site 被引用文献6件
  • John H. Rex
    <!--label omitted: 1-->Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston, Texas 770301;
  • Michael A. Pfaller
    <!--label omitted: 2-->University of Iowa College of Medicine, Iowa City, Iowa 522422;
  • Thomas J. Walsh
    <!--label omitted: 3-->Infectious Diseases Section, Pediatric Branch, National Cancer Institute, Bethesda, Maryland 208923;
  • Vishnu Chaturvedi
    <!--label omitted: 4-->New York State Department of Health, Albany, New York 122014;
  • Ana Espinel-Ingroff
    <!--label omitted: 5-->Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 232985;
  • Mahmoud A. Ghannoum
    <!--label omitted: 6-->Department of Dermatology, Case Western Reserve University, Cleveland, Ohio 441066;
  • Linda L. Gosey
    <!--label omitted: 7-->U.S. Food and Drug Administration, Rockville, Maryland 208577;
  • Frank C. Odds
    <!--label omitted: 8-->Institute of Medical Sciences, Aberdeen, United Kingdom8;
  • Michael G. Rinaldi
    <!--label omitted: 9-->Veterans Administration Medical Center, San Antonio, Texas 782849;
  • Daniel J. Sheehan
    <!--label omitted: 10-->Pfizer Inc., Pfizer Pharmaceuticals Group, New York, New York 1001710; and
  • David W. Warnock
    <!--label omitted: 11-->Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia11

抄録

<jats:sec><jats:title>SUMMARY</jats:title><jats:p>Development of standardized antifungal susceptibility testing methods has been the focus of intensive research for the last 15 years. Reference methods for yeasts (NCCLS M27-A) and molds (M38-P) are now available. The development of these methods provides researchers not only with standardized methods for testing but also with an understanding of the variables that affect interlaboratory reproducibility. With this knowledge, we have now moved into the phase of (i) demonstrating the clinical value (or lack thereof) of standardized methods, (ii) developing modifications to these reference methods that address specific problems, and (iii) developing reliable commercial test kits. Clinically relevant testing is now available for selected fungi and drugs: Candida spp. against fluconazole, itraconazole, flucytosine, and (perhaps) amphotericin B; Cryptococcus neoformans against (perhaps) fluconazole and amphotericin B; and Aspergillus spp. against (perhaps) itraconazole. Expanding the range of useful testing procedures is the current focus of research in this area.</jats:p></jats:sec>

収録刊行物

被引用文献 (6)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ